Home The Word Brain My Amedeo FAQ Privacy About   


Chinese Coaching

Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.


  Pulmonary Hypertension, January 2026

Free Subscription


Abstracts

Retrieve all available abstracts of the following 109 articles:
HTML format


 

Single Articles

  1. LIU C, Lu JW, Wu CH, Ho YJ, et al
    Adjuvant Molecular Hydrogen Therapy in SLE-associated Pulmonary Arterial Hypertension: A Case Report on Immunomodulatory Effects on Regulatory and Effector Lymphocytes.
    In Vivo. 2026;40:551-560.
    PubMed    
    Abstract available

  2. XU W, Shen Y, Wan Z, Guo J, et al
    Macrophage-driven immunopathology in pulmonary arterial hypertension: from mechanisms to targeted therapies.
    Front Immunol. 2025;16:1721071.
    PubMed    
    Abstract available

  3. FERRARA F, Castaldo R, Gargani L, Benjamin N, et al
    Predicting Exercise Pulmonary Hypertension: The RIGHT-NET Machine Learning model A Pilot Study.
    Transl Res. 2025 Dec 30:S1931-5244(25)00121-5. doi: 10.1016/j.trsl.2025.
    PubMed    
    Abstract available

  4. DESHMUKH SN, Anand A, Deore SS
    Haemodynamics and post-exercise recovery response in chronic obstructive pulmonary disease-pulmonary hypertension and interstitial lung disease-pulmonary hypertension: An appraisal.
    Lung India. 2026;43:105-106.
    PubMed    


  5. MALAKOUTIKHAH M, Kalantari F, Nematollahi A, Moradi H, et al
    Severe pulmonary hypertension associated with unilateral pulmonary artery hypoplasia: A case report.
    ARYA Atheroscler. 2025;21:1-7.
    PubMed    
    Abstract available

  6. MARTINEZ-SOLANO J, Bermejo-Fernandez J, Gonzalez-Mansilla A, Garcia-Orta R, et al
    The role of the bone morphogenetic protein receptor 2 pathway in group 2 pulmonary hypertension secondary to valvular heart disease.
    ERJ Open Res. 2025;11:00543-2025.
    PubMed    
    Abstract available

  7. J JB, R J, Murugan S, G SL, et al
    Identification of upregulated genes in pulmonary hypertension using RNA sequencing profiling.
    Bioinformation. 2025;21:3105-3109.
    PubMed    
    Abstract available

  8. TITZ A, Muller J, Schneider SR, Lichtblau M, et al
    Comparison of Invasive Versus Non-Invasive Pulse Contour-Based Cardiac Output Measurements at Rest and During Exercise in Pulmonary Hypertension.
    J Clin Med. 2025;14:8971.
    PubMed    
    Abstract available

  9. TITOLO AC, Ferrocino M, Biagi E, Rizzo L, et al
    Neonatologist-Performed Echocardiography in Neonatal Pulmonary Hypertension: A Narrative Review of the Literature.
    Diagnostics (Basel). 2025;15:3154.
    PubMed    
    Abstract available

  10. HUANG W, Zheng R, Gong L, Zhang Y, et al
    Roles of Lipid Metabolism in Pulmonary Hypertension: Friend or Foe?
    Biomolecules. 2025;15:1679.
    PubMed    
    Abstract available

  11. CSOMA B, Szucs G, Bikov A, Rozgonyi ZD, et al
    Alveolar and Bronchial Nitric Oxide Parameters in Pre-Capillary Pulmonary Hypertension.
    Biomedicines. 2025;13:2957.
    PubMed    
    Abstract available

  12. WANG M, Lu J, Li X, Xie H, et al
    Construction of an early diagnostic model for pulmonary hypertension based on aging-related signature genes and identification of potential therapeutic targets.
    Sci Rep. 2025;15:44788.
    PubMed    
    Abstract available

  13. LARSON J, Khorasani S, Laurenzo S, Chiu S, et al
    Leveraging Vascular Over Ventricular Ratios in Observational Chronic Thromboembolic Pulmonary Hypertension and Acute Pulmonary Embolism Cohorts to Decode Clot Chronicity on Computed Tomography Angiography.
    Pulm Circ. 2025;15:e70223.
    PubMed    
    Abstract available

  14. SANTACRUZ JC, Mantilla MJ, Pulido S, Agudelo C, et al
    Pulmonary Hypertension in Systemic Lupus Erythematosus: Current Evidence and Future Directions.
    Cureus. 2025;17:e97863.
    PubMed    
    Abstract available

  15. YAGDIRAN B, Uchehara CU, Safak A, Cekmen N, et al
    The relationship between preoperative pulmonary hypertension risk in liver transplant and vascular and biliary complications in the postoperative period.
    Diagn Interv Radiol. 2025 Dec 29. doi: 10.4274/dir.2025.253707.
    PubMed    
    Abstract available

  16. PARLAK ES, Uzun BAA, Gungor K, Ceylan EG, et al
    Evaluation of Predisposing Factors and Coexisting Diseases in the Development of Chronic Thromboembolic Pulmonary Disease.
    Clin Respir J. 2025;19:e70147.
    PubMed    
    Abstract available

  17. LIU Y, Deng X, He C, Lv S, et al
    NDRG1-HIF1alpha interaction in hypoxic signaling for pulmonary hypertension.
    Int J Biol Macromol. 2025;339.
    PubMed    
    Abstract available

  18. DUBLE EH, Springer CM, Koster LS
    Association of pulmonary arterial end-diastolic forward flow and right heart remodeling in dogs with congenital pulmonic stenosis and precapillary pulmonary hypertension.
    J Vet Cardiol. 2025;64:14-24.
    PubMed    
    Abstract available

  19. DZIKOWSKA-DIDUCH O, Dudzik-Niewiadomska I, Kurnicka K, Lichodziejewska B, et al
    Elevated tricuspid peak systolic gradient with enlarged right ventricle present during acute episode of pulmonary embolism predict subsequent chronic thromboembolic pulmonary hypertension.
    Thromb J. 2025 Dec 27. doi: 10.1186/s12959-025-00818.
    PubMed    


  20. JU G, Zhang S, Zhang J, Dong F, et al
    Sodium Houttuyfonate Alleviates Monocrotaline-induced Pulmonary Hypertension by Regulating Canonical Transient Receptor Potential Channel Proteins.
    Eur J Pharmacol. 2025 Dec 25:178507. doi: 10.1016/j.ejphar.2025.178507.
    PubMed    
    Abstract available

  21. HE R, Liu J, Tang X, Liu H, et al
    Reversible Pulmonary Hypertension in CblC Deficiency (MMACHC c.80 A>G): long-term outcomes of metabolic and PH-targeted therapy.
    Pediatr Res. 2025 Dec 26. doi: 10.1038/s41390-025-04720.
    PubMed    
    Abstract available

  22. ZHANG Y, Zhang Y, Yang S, Huang Y, et al
    Risk prediction and therapeutic targets for incident pulmonary hypertension: a large-scale proteomic profiling and Mendelian randomization study.
    Front Med. 2025 Dec 27. doi: 10.1007/s11684-025-1183.
    PubMed    
    Abstract available

  23. BUSCHULTE K, Kabitz HJ, Hagmeyer L, Hammerl P, et al
    Baseline characteristics from the EXCITING-ILD registry.
    BMJ Open Respir Res. 2025;12:e002902.
    PubMed    
    Abstract available

  24. CHEN M, He Y, Zhu X, Luo Y, et al
    Baicalin attenuates pulmonary hypertension by targeting AMPK/CPT1A-mediated fatty acid metabolism.
    Phytomedicine. 2025;150:157703.
    PubMed    
    Abstract available

  25. SONNICK MA, Laothamatas KC, Anderson MR, Stewart D, et al
    Waitlist outcome differences for pulmonary hypertension patients are worse in the CAS era.
    JHLT Open. 2025;11:100443.
    PubMed    
    Abstract available

  26. MACIAS PRADO FE, German Gaibor JM, Portaluppi Cervantes RE, Campozano Burgos MA, et al
    Beyond Childhood: Percutaneous Closure of an Aortopulmonary Window with Severe Pulmonary Hypertension in an Adult Woman - A Case Report.
    Interv Cardiol. 2025;20:e34.
    PubMed    
    Abstract available

  27. BEN DAVID R, Gurfinkel R, Nalbandyan K, Roth I, et al
    [Pulmonary Tumor Thrombotic Microangiopathy - Case Report].
    Harefuah. 2025;165:647-650.
    PubMed    
    Abstract available

  28. KERRIGAN WJ, Church AC, Herrick AL
    Systemic Sclerosis-Recent Advances in Diagnosis and Management.
    Br J Hosp Med (Lond). 2025;86:1-21.
    PubMed    
    Abstract available

  29. FUJIWARA M, Yamamura A, Miyaki R, Amano T, et al
    Enhanced Yoda1-induced vasoconstriction in pulmonary arterial smooth muscle from monocrotaline-induced pulmonary hypertensive rats.
    Biochem Biophys Res Commun. 2025;797:153183.
    PubMed    
    Abstract available

  30. NEWMAN J, Ghani H, Munagala S, Otter E, et al
    The Pulmonary Hypertension Global Patient Survey: understanding the experiences and perspectives of patients.
    ERJ Open Res. 2025;11:00297-2025.
    PubMed    
    Abstract available

  31. GILLMEYER KR
    Insights from the Pulmonary Hypertension Global Patient Survey: challenges in pulmonary hypertension care abound but so do opportunities.
    ERJ Open Res. 2025;11:00963-2025.
    PubMed    
    Abstract available

  32. JENKIN I, Dimopoulos K, Nathan SD, Herbert S, et al
    Survival in patients with pulmonary hypertension associated with fibrotic interstitial lung disease (ILD) is independent of ILD subtype.
    ERJ Open Res. 2025;11:00235-2025.
    PubMed    
    Abstract available

  33. MICKAEL C, Kabwe JC, Fonseca Balladares D, Bai AS, et al
    Pulmonary Hypertension Associated With Sickle Cell Disease and Schistosomiasis.
    Pulm Circ. 2025;15:e70230.
    PubMed    
    Abstract available

  34. LOKHANDWALA A, Salman Al-Timimi A, Da Silva T, Nourouzpour S, et al
    Clinical implications of frailty in hospitalized patients with pulmonary arterial hypertension.
    Chron Respir Dis. 2025;22:14799731251408844.
    PubMed    
    Abstract available

  35. DAGHER C, Akiki M, Swanson K, Carollo B, et al
    Use of Sotatercept to Facilitate Transition From Intravenous to Oral Prostacyclin Therapy.
    Clin Respir J. 2025;19:e70149.
    PubMed    
    Abstract available

  36. TAKITA Y, Morishita J, Park S, Goda A, et al
    Mindfulness-Based Self-Management Program Using a Mobile Application for Patients with Pulmonary Hypertension: A Single-Arm Feasibility Study.
    JMIR Cardio. 2025 Dec 16. doi: 10.2196/79639.
    PubMed    
    Abstract available

  37. WANG X, He Y, Li K, Xue Z, et al
    TRAF6 mediates vascular remodeling via endoplasmic reticulum stress-mitophagy in hypoxic pulmonary hypertension.
    Free Radic Biol Med. 2025 Dec 20:S0891-5849(25)01448.
    PubMed    
    Abstract available

  38. BEIS I, Dipla K, Haidich AB, Boutou A, et al
    Safety and efficacy of exercise training in patients with pulmonary hypertension: a systematic review and meta-analysis.
    Eur J Appl Physiol. 2025 Dec 22. doi: 10.1007/s00421-025-06104.
    PubMed    


  39. SEEGER W
    The Discovery of Inhaled Prostanoids for Pulmonary Hypertension.
    Pulm Circ. 2025;15:e70192.
    PubMed    


  40. LEE L, Cao S, Miles CB, Troy MP, et al
    Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension: Patient Selection, Procedural Pearls, and Expected Outcomes.
    Semin Intervent Radiol. 2025;42:509-517.
    PubMed    
    Abstract available

  41. MERK J, Yung D, Wright JN, Kapur RP, et al
    Noncirrhotic Portopulmonary Hypertension Due to Hepatoportal Sclerosis in Adams-Oliver Syndrome.
    Pediatrics. 2026;157:e2025073243.
    PubMed    
    Abstract available

  42. HU Y, Wang Y, Tan W, Zhao C, et al
    Design and Optimization of LOXL2 and sGC Dual-Target Regulators Targeting Extracellular Matrix Dysregulation and Vasodilation for the Treatment of Pulmonary Arterial Hypertension.
    J Med Chem. 2025;68:26547-26573.
    PubMed    
    Abstract available

  43. ZULFIQAR H, Alali J, Granlund B, Feng J, et al
    Interleukin-35 alleviates pulmonary arterial hypertension by suppressing the VEGFA/VEGFR2 signaling pathway.
    Life Sci. 2026;385:124144.
    PubMed    
    Abstract available

  44. ZHANG JY, Zhang R, Liu J, Chen L, et al
    Agomelatine alleviates hypoxia-induced pulmonary arterial hypertension by activating mitophagy via the SIRT1/FoxO1/ULK1 signaling pathway.
    Biochem Pharmacol. 2026;244:117624.
    PubMed    
    Abstract available

  45. WANG S, Song S, Feng H, Sun H, et al
    tRF-31-PS5P4PW3FJHP inhibits hypoxia-induced proliferation of pulmonary artery endothelial cells by regulating EDN1 splicing via binding to LSM4.
    Eur J Pharmacol. 2026;1011:178426.
    PubMed    
    Abstract available

  46. ZOLTY R
    Antiproliferative therapies in pulmonary arterial hypertension.
    Expert Opin Pharmacother. 2025;26:1895-1911.
    PubMed    
    Abstract available

  47. AHMAD A, Zhang S, Ren Q, Li L, et al
    Transthoracic echocardiography of left ventricular underfilling improves risk stratification in pulmonary arterial hypertension.
    Sci Rep. 2025;15:45718.
    PubMed    
    Abstract available

  48. MOSS ME, Smit MC, Klouda T, Zhao Z, et al
    Pericytes and Lung Vascular Remodeling.
    Arterioscler Thromb Vasc Biol. 2026;46:17-26.
    PubMed    
    Abstract available

  49. GARCIA KM, Hardie BA, Valdez-Jasso D
    Sex-Specific Interventricular Septum Mechanics in Pulmonary Arterial Hypertension.
    Ann Biomed Eng. 2026;54:29-40.
    PubMed    
    Abstract available

  50. BETTER J, Leroy S, Ninaber MK, Trakada G, et al
    VE/VCO(2) at ventilatory threshold and peak VO(2) in CPET studies of patients with scleroderma-associated PAH: A systematic review and meta-analyses.
    Autoimmun Rev. 2026;25:103942.
    PubMed    
    Abstract available

  51. SHI W, Chen L, Zhang W, He P, et al
    YAP-mediated glycolysis promotes pulmonary arterial smooth muscle cell proliferation in pulmonary arterial hypertension.
    J Biol Chem. 2025;301:110836.
    PubMed    
    Abstract available

  52. HUANG Y, Zhang C, Ye H, Sun X, et al
    A Noninvasive Prognostic Model for Pulmonary Arterial Hypertension Associated With Connective Tissue Diseases Based on Multislice Chest Computed Tomography Parameters.
    J Thorac Imaging. 2026;41:e0855.
    PubMed    
    Abstract available

  53. ZHOU L, Luo J, Tan C, Li Y, et al
    Worldwide Burden of Pulmonary Arterial Hypertension in Adults Aged 65 Years and Older From 1990 to 2021.
    J Am Geriatr Soc. 2025;73:3700-3707.
    PubMed    
    Abstract available

  54. TRUONG R, Davis S, Rosario N, Wollen J, et al
    Sotatercept: A New Frontier in Pulmonary Arterial Hypertension Treatment.
    Ann Pharmacother. 2026;60:163-174.
    PubMed    
    Abstract available

  55. POST TE, Denney C, Cohen A, Jordan J, et al
    Human hypoxia models in aerospace medicine: Potential applications for human pharmacological research.
    Br J Clin Pharmacol. 2026;92:58-72.
    PubMed    
    Abstract available

  56. AKOPYAN K, Peterson J, Amoda O, Khasawneh M, et al
    Echocardiographic Pulmonary Hypertension in Patients Positive for Myositis-Specific and Myositis-Associated Antibodies.
    J Clin Med. 2025;15:77.
    PubMed    
    Abstract available

  57. KOOK H, Kim W, Heo R, Kim K, et al
    Current Perspectives on Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension.
    J Clin Med. 2025;15:51.
    PubMed    
    Abstract available

  58. ZHANG X, Chen M, Wang R, Liu R, et al
    Flavonoids: Potential New Drug Candidates for Attenuating Vascular Remodeling in Pulmonary Hypertension.
    Int J Mol Sci. 2025;27:210.
    PubMed    
    Abstract available

  59. IANCU DG, Cristescu L, Mares RG, Varga A, et al
    Reply to Pagnoni et al. Clarifying the Clinical Utility of NTAR/RGR for PAH and CTEPH. Comment on "Iancu et al. Evaluating NT-proBNP-to-Albumin (NTAR) and RDW-to-eGFR (RGR) Ratios as Biomarkers for Predicting Hospitalization Duration and Mortality in
    Diagnostics (Basel). 2025;16:56.
    PubMed    
    Abstract available

  60. PAGNONI G, Vicenzi A, Coppi F
    Clarifying the Clinical Utility of NTAR/RGR for PAH and CTEPH. Comment on Iancu et al. Evaluating NT-proBNP-to-Albumin (NTAR) and RDW-to-eGFR (RGR) Ratios as Biomarkers for Predicting Hospitalization Duration and Mortality in Pulmonary Arterial Hypert
    Diagnostics (Basel). 2025;16:55.
    PubMed    
    Abstract available

  61. ADU-AMANKWAAH J, Shi Y, Song H, Ma Y, et al
    Correction: Signaling pathways and targeted therapy for pulmonary hypertension.
    Signal Transduct Target Ther. 2026;11:12.
    PubMed    


  62. ZHANG Y, Ye J, Chen J, Chen J, et al
    Pharmacovigilance Analysis of Sotatercept for the Treatment of Pulmonary Arterial Hypertension Based on FAERS Database.
    Cardiovasc Toxicol. 2026;26:12.
    PubMed    
    Abstract available

  63. VACHRUSHEV NS, Karpov AA, Shilenko LA, Vaulina DD, et al
    Lung Tissue RNA Sequencing Shows Dysregulation of the Bronchial Epithelium in a Rat Model of Chronic Thromboembolic Pulmonary Hypertension.
    Bull Exp Biol Med. 2026 Jan 9. doi: 10.1007/s10517-026-06549.
    PubMed    
    Abstract available

  64. PRISCO SZ, Kantorovich A, Liu Y, Sahay S, et al
    Global Resource Disparities Between Pulmonary Hypertension Centers: Results From the International Survey by the PVRI IDDI Access to Care Workstream.
    Pulm Circ. 2026;16:e70229.
    PubMed    
    Abstract available

  65. DAOUD A, Lopez PP, Mombeini H, Zaeske A, et al
    Echocardiographic Deformation Imaging of the Right Atrium: A New Paradigm in Noninvasive Hemodynamic Assessment.
    Curr Cardiol Rep. 2026;28:11.
    PubMed    
    Abstract available

  66. KHAN SA, Parikh T, Rao A, Agrawal A, et al
    In-hospital Mortality Patterns and Readmissions in Patients With Chronic Obstructive Pulmonary Disease: An Analysis of the Role of Pulmonary Hypertension.
    COPD. 2026;23:2582902.
    PubMed    
    Abstract available

  67. SHIMOJO T, Tada T, Ito H, Kinoshita H, et al
    Pulmonary tumour thrombotic microangiopathy or chronic thromboembolic pulmonary hypertension?-diagnosed by pulmonary wedge aspiration cytology using a Swan-Ganz catheter: a case report.
    Eur Heart J Case Rep. 2025;10:ytaf648.
    PubMed    
    Abstract available

  68. ZHU Y, He J, Cai M, Wen L, et al
    Safety of a novel portable inhaled nitric oxide generator for therapy of persistent pulmonary hypertension in neonates: a case series study.
    Transl Pediatr. 2025;14:3305-3317.
    PubMed    
    Abstract available

  69. MIRZAMOHAMMADI S, Shirazi N, Deravi N, Zadeh RH, et al
    Coronary Artery Calcium Score as a Potential Non-Invasive Marker for Pulmonary Artery Hypertension.
    Acta Med Indones. 2025;57:445-453.
    PubMed    
    Abstract available

  70. WANG X, Song X, Yu F, Yu Y, et al
    A Superoxide Anion-Responsive NIR Fluorogenic Probe Unravels Aucubin's Dual-Axis Therapeutic Mechanism in Hypoxic Pulmonary Hypertension via Ferroptosis Suppression and Oxidative Injury Mitigation.
    Anal Chem. 2026 Jan 7. doi: 10.1021/acs.analchem.5c05233.
    PubMed    
    Abstract available

  71. KONDOH Y, Ogura T, Nishiyama O, Kinoshita H, et al
    Corrigendum to "Long-term effects of inhaled treprostinil in Japanese patients with pulmonary hypertension associated with interstitial lung disease" [Respir Invest, Volume 64, Issue 1, January 2026, 101340].
    Respir Investig. 2026 Jan 6:101365. doi: 10.1016/j.resinv.2025.101365.
    PubMed    


  72. SEERAM VK, Boppana LKT
    Unilateral absence of pulmonary artery presenting with pulmonary hypertension in two adults.
    BMJ Case Rep. 2026;19:e269028.
    PubMed    
    Abstract available

  73. ARTHUR ME, Mudaliar P, Sakharpe A, Odo N, et al
    Between a Rock and a Hard Place: Hip Fracture Repair in an Elderly Patient with Severe Cardiac Comorbidities and Limited Options: A Problem-Based Learning Discussion.
    A A Pract. 2026;20:e02058.
    PubMed    
    Abstract available

  74. VENKATESHVARAN A, Lindow T, Jumatate R, Kovacs A, et al
    Linking Energetic Inefficiency to Ventriculoarterial Uncoupling in Pulmonary Hypertension.
    Echocardiography. 2026;43:e70389.
    PubMed    
    Abstract available

  75. HAO J, Fang G, Li X, Wang T, et al
    Targeting Macrophage Crosstalk to PASMC by Blunting Inflammatory Phenotype Via SerpinB1 Protects Against Hypoxia-Induced Pulmonary Hypertension.
    Hypertension. 2026 Jan 7. doi: 10.1161/HYPERTENSIONAHA.125.25832.
    PubMed    
    Abstract available

  76. HUANG Y, Yan S, Zhu J, Zhang W, et al
    SPP1 May Play an Important Role in the Carcinoid Nature of PAH.
    Mediators Inflamm. 2025;2025:7457106.
    PubMed    
    Abstract available

  77. PAK O, Weissmann N
    Is it the extracellular matrix?-smooth muscle fate in pulmonary hypertension secondary to left heart disease.
    Cardiovasc Res. 2026 Jan 7:cvaf261. doi: 10.1093.
    PubMed    


  78. LI G, Zhao Z, Machitani M, Ishikawa R, et al
    Elucidation of mechanisms underlying the therapeutic effects of cordycepin on pulmonary hypertension, with a focus on cell senescence and gut microbiota.
    Biomed Pharmacother. 2026;194:118923.
    PubMed    
    Abstract available

  79. YUE K, Qu X, Zhang F, Zhao M, et al
    Pulmonary hypertension caused by fibrosing mediastinitis: A case report and literature review.
    Medicine (Baltimore). 2026;105:e46180.
    PubMed    
    Abstract available

  80. KIM TH, Youn SE, Chung SH
    Clinical impact of treprostinil in neonates with persistent pulmonary hypertension refractory to inhaled nitric oxide: A retrospective cohort study.
    Medicine (Baltimore). 2026;105:e46984.
    PubMed    
    Abstract available

  81. BELKIN MN, Fudim M, Baratto C, Grinstein J, et al
    Standardization of Baseline and Provocative Invasive Hemodynamic Protocols for the Evaluation of Heart Failure and Pulmonary Hypertension: A Scientific Statement From the American Heart Association.
    Circ Heart Fail. 2026 Jan 6:e000088. doi: 10.1161/HHF.0000000000000088.
    PubMed    
    Abstract available

  82. QIU Y, Lyu X, Zhang D, Xu H, et al
    Gut Microbiota in Pulmonary Arterial Hypertension: Murine Models and Human Microbial Signatures, Pathogenic Mechanisms, and Emerging Therapeutic Avenues.
    Compr Physiol. 2026;16:e70094.
    PubMed    
    Abstract available

  83. WANG Q, Liu J, Li R, Kong S, et al
    Macrophage kappa-opioid receptor inhibits hypoxic pulmonary hypertension progression and right heart dysfunction via an SCD1-dependent anti-inflammatory response.
    Genes Dis. 2025;13:101604.
    PubMed    
    Abstract available

  84. WANG M, Zhang M, Chen J, Wang Y, et al
    Nuclear SIRT6 depletion activates LINE1-cGAS-STING pathway to induce PASMCs senescence in hypoxic pulmonary hypertension.
    Cell Signal. 2026;139:112351.
    PubMed    
    Abstract available

  85. DING H, Zeng M, Sun B, Deng F, et al
    Measurement of Pulmonary Artery Pressure in Rats Using Right Heart Catheterization.
    J Vis Exp. 2025;.
    PubMed    
    Abstract available

  86. BAHMANI F, Pearce D, Southern K, Nwadiaro K, et al
    Fluid Flow Analysis of Pulmonary Hypertension in End Stage Renal Disease: A NAMS-Driven Case Study.
    J Biomech Eng. 2026 Jan 5:1-29. doi: 10.1115/1.4070760.
    PubMed    
    Abstract available

  87. HEGAZY Y, Abdallah A, Salem A, Assaker A, et al
    When the Skin Tells a Pulmonary Story: A Case of Neurofibromatosis Type 1-Associated Pulmonary Hypertension.
    Cureus. 2025;17:e98338.
    PubMed    
    Abstract available

  88. KURAHARA LH
    [Cellular senescence in pulmonary hypertension].
    Nihon Yakurigaku Zasshi. 2026;161:55-56.
    PubMed    


  89. YOKOKAWA T, Nishiura K, Akama J, Kiko T, et al
    Significance of 14-3-3 Epsilon for Right Ventricular Failure Associated with Pulmonary Hypertension.
    Intern Med. 2026 Jan 2. doi: 10.2169/internalmedicine.6383.
    PubMed    
    Abstract available

  90. NAEEM A, Bolaji O, Kidess GG, Fahed J, et al
    Durability of sotatercept response in pulmonary hypertension: Insights from extended real-world follow-up.
    Int J Cardiol. 2026;447:134150.
    PubMed    
    Abstract available

  91. SOMECH J, Zahler D, St-Germain R, Roshdy O, et al
    Rapidly reversible precapillary pulmonary hypertension in a patient with scurvy.
    Can J Cardiol. 2026 Jan 2:S0828-282X(25)01621-6. doi: 10.1016/j.cjca.2025.
    PubMed    


  92. BARANYAI T, Takacs P, Szabo B, Nagy Z, et al
    [Balloon pulmonary angioplasty in Gottsegen National Cardiovascular Center - results of the first 2 years].
    Orv Hetil. 2026;167:23-29.
    PubMed    
    Abstract available

  93. ROSHANZAMIR Z, Mohammadi F, Shirzadi R
    Pulmonary hypertension in pediatric patients with cystic fibrosis during acute pulmonary exacerbations: prevalence and associated factors.
    BMC Pulm Med. 2026 Jan 3. doi: 10.1186/s12890-025-04095.
    PubMed    
    Abstract available

  94. KAM THH, Kam KKH, Wong MKL, Yan BPY, et al
    Haemodynamic and clinical impacts of switching phosphodiesterase-5 inhibitors to riociguat in patients with chronic thromboembolic pulmonary hypertension (CTEPH) after balloon pulmonary angioplasty (BPA) - a prospective cohort study.
    BMC Pulm Med. 2026 Jan 3. doi: 10.1186/s12890-025-04069.
    PubMed    
    Abstract available

  95. HAN R, Wang Y, Lu X, Li W, et al
    Comprehensive profiling of lactylation-associated genes in pulmonary hypertension through bulk and single-cell RNA sequencing integration.
    Respir Res. 2026 Jan 3. doi: 10.1186/s12931-025-03446.
    PubMed    
    Abstract available

  96. GUAN A, Dai Z, Lin J, Chen Q, et al
    Global disease burden of pulmonary arterial hypertension: patterns and inequality in 1990-2021, with projections to 2035.
    BMC Public Health. 2026;26:4.
    PubMed    
    Abstract available

  97. LIU BY, Xie M
    [Application and research progress of artificial intelligence in the diagnosis and treatment of rare lung diseases].
    Zhonghua Jie He He Hu Xi Za Zhi. 2026;49:78-83.
    PubMed    
    Abstract available

  98. MIHAI A
    Right Ventricular Global Wasted Work and RV-PA Coupling: Implications for Pulmonary Hypertension.
    Echocardiography. 2026;43:e70384.
    PubMed    


  99. SPAGNOLO P, Dhanani Z, Cameli P, Fiorentu G, et al
    Advanced Pulmonary Sarcoidosis.
    Semin Respir Crit Care Med. 2025;46:564-575.
    PubMed    
    Abstract available

  100. QIAO X, Su D, Qin S, Shang L, et al
    Pulmonary arterial hypertension increases the risk of female sexual dysfunction: a systematic review and meta-analysis.
    J Sex Med. 2026;23:qdaf294.
    PubMed    
    Abstract available

  101. ZHI C, Shi X, Chen S, Cai Z, et al
    Single-cell transcriptome analysis reveals critical causative candidates for Down syndrome-related lung diseases.
    J Genet Genomics. 2026;53:75-86.
    PubMed    
    Abstract available

  102. YANG JZ, Madani MM, Papamatheakis DG, Fernandes TM, et al
    CHEST How I Do It: Management of chronic thromboembolic pulmonary hypertension before and after pulmonary thromboendarterectomy.
    Chest. 2026 Jan 2:S0012-3692(25)05963-X. doi: 10.1016/j.chest.2025.
    PubMed    
    Abstract available

  103. ZAFEIROPOULOS S, Ahmed U, Bekiaridou A, Jayaprakash N, et al
    Correction to: Ultrasound Neuromodulation of an Anti-Inflammatory Pathway at the Spleen Improves Experimental Pulmonary Hypertension.
    Circ Res. 2026;138:e000740.
    PubMed    


  104. SHEN Y, Bisserier M
    ADAR1-Mediated RNA Editing Regulates Innate Immunity in Pulmonary Hypertension.
    Circ Res. 2026;138:e327782.
    PubMed    


  105. GUO S, Pan T, Yan X, Cheng Y, et al
    Differential Impact of Recruited and Resident Macrophages on Hypoxia-Induced Pulmonary Hypertension.
    Circ Res. 2025 Dec 31. doi: 10.1161/CIRCRESAHA.125.326472.
    PubMed    
    Abstract available

  106. OLLOSU M, Tripodi VF, Aresu C, Ledda G, et al
    Efficacy and Safety of Pulmonary Vasodilator and Inodilator Drugs in Congenital Heart Disease Surgery: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
    J Cardiothorac Vasc Anesth. 2026;40:333-346.
    PubMed    
    Abstract available

  107. SHIGEMURA N, Hage CA
    Reframing Surgical Decision-Making When Treating Severe Pulmonary Hypertension: Beyond the Binary of Lungs Alone versus Combined Heart-Lung Transplantation.
    J Heart Lung Transplant. 2025 Dec 20:S1053-2498(25)02466.
    PubMed    


  108. MINATSUKI S, Hatano M, Funakoshi K, Taniguchi Y, et al
    Significance of diffusing capacity of the lungs for carbon monoxide on chronic thromboembolic pulmonary hypertension.
    Thorax. 2026 Jan 7:thorax-2025-223670. doi: 10.1136/thorax-2025-223670.
    PubMed    
    Abstract available

  109. WU C, Wang Z, Luo Y, Sun H, et al
    Global, regional, and national burden of pulmonary arterial hypertension from 1990 to 2021 and projection to 2050: A systematic analysis for the global burden of disease study 2021.
    PLoS One. 2025;20:e0338335.
    PubMed    
    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Pulmonary Hypertension is free of charge.


;